An Ames-based pharmaceutical company has entered into a $150 million deal to further develop its cancer therapies.
NewLink Genetics said today that it has entered into an exclusive license agreement with Genentech, a San Francisco-based biotechnology firm.
08:10 Top EU lawmaker intervenes to try to save Canada trade pact1
01:27 Is TPP the next trade domino to fall as Canada-EU trade deal ends in tears2
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner2
20:28 With Europe-Canada Deal Near Collapse, Globalization’s Latest Chapter Is History